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Abstract
Summary This study evaluated the association of vitaminD and
bone markers with the development osteoporosis in Palestinian
postmenopausal women. Even though vitamin D deficiency
was very high for the recruited subjects, it was not associated
with osteoporosis except for bones of the hip. Age and obesity
were the strongest determining factors of the disease.
Purpose The purpose of this study was to investigate the as-
sociation of bone mineral density (BMD) with serum vitamin
D levels, parathyroid hormone (PTH), calcium, obesity, and
bone turnover markers in Palestinian postmenopausal women.
Methods Three hundred eighty-two postmenopausal women
(≥45 years) were recruited from various women clinics for
BMD assessment (131 women had osteoporosis and 251 were
normal and served as controls). Blood samples were obtained
for serum calcium, PTH, 25(OH)D, bone formation (N-termi-
nal propeptide (PINP)), and bone resorption (serum C-
terminal telopeptide of type I collagen (CTX1)) markers.
Results Women with osteoporosis had statistically significant
lower mean weight, height, body mass index (BMI), and serum
calcium (p < 0.05) compared to controls. No significant
differences were detected between the mean values of bone
turnover markers (CTX and PINP), 25(OH)D, and PTH of
the two groups. Women with vitamin D deficiency (severe
and insufficiency) represented 85.9% of the study subjects.
Multiple and logistic regression showed that age and BMI
significantly affected BMD and vitamin D had a significant
association with BMD only at the lumbar spine. BMI was
positively correlated with BMD and PTH but negatively
correlated with vitamin D. Logistic regression showed that
the odds ratio (OR) for having osteoporosis decreased with
increasing BMI (overweight OR = 0.11, p = 0.053; obese
OR = 0.05, p = 0.007).
Conclusions There was no direct correlation between BMD
and PTH, bone turnover markers, and vitamin D except at the
lumbar spine. A negative correlation between BMD and age
and a positive correlation with BMI were observed. The pro-
tective effect of obesity on osteoporosis was complicated by
the effect of obesity on vitamin D and PTH.
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Introduction
Osteoporosis is a widespread disease characterized by
significant decrease in bone quality as a consequence of
deterioration in bone microarchitecture and low bone mass
[1, 2]. Primary osteoporosis is common in postmenopausal
women but can also affect men at an older age. Common
bone fractures constitute the major cause of high mortality
and morbidity among patients with mounting cost on health
services [3]. Bone mineral density (BMD) is determined by
several non-genomic (nutritional, hormonal) and genetic
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factors [4, 5]. Genome wide association studies provided pos-
itive association between certain loci in the genome and oste-
oporosis [6].
Vitamin D plays a central role in bone formation and re-
modeling [7–9]. Several studies have documented the impor-
tance of maintaining adequate levels of serum vitamin D to
protect against bone fracture [10–15]. Vitamin D deficiency is
currently a major health concern worldwide [7, 16, 17].
Although the Middle East countries enjoy sunshine year
around, their populations suffer from significant vitamin D
deficiency in all ages and have one of the highest rates of
rickets in the world [10, 15, 18, 19]. Several factors contribute
to the development of vitamin D deficiency and its negative
physiological impact on bones including decreased dietary
intake, inadequate production of the vitamin in the skin, and
disturbances in the production of the active hormonal form of
vitamin D [10, 15, 20–23]. Recently, vitamin D deficiency,
which is common among the Saudi Arabian population,
reached 41–64% among young females 12–18 years old
[24–27]. In addition to the vitamin D status, mutations in the
vitamin D receptor markedly contribute to the complications
of vitamin D deficiency on bone health [28, 29].
Bone remodeling is a slow and life-long active process
influenced by vitamin D receptor activity in bone cells [30].
The magnitude of bone remodeling is evaluated through the
measurement of specific bone turnover markers including se-
rum carboxy-terminal telopeptide (s-CTX) and the N-terminal
propeptide (PINP) of procollagen type I [31–33].
Previously, we reported relatively high prevalence of post-
menopausal osteoporosis in the Palestinian population that
was associated with poor knowledge and awareness about
the various risk factors of the disease [34]. Body mass index
positively correlates with BMD [35], while very low BMI
represents an independent osteoporotic fracture risk [36].
However, obesity does not protect against all osteoporotic
fractures [37] and bone recovery after fractures is worse
among obese compared to non-obese individuals [38].
In the present study, we investigated the correlation be-
tween BMD at various specific skeletal sites (total hip, lumbar
L1–L4 spine, and femoral neck) with serum levels of
25(OH)D, parathyroid hormone (PTH), calcium, specific
markers of bone formation, and bone resorption, in addition
to other non-genomic factors including age, height, weight,
and BMI among Palestinian postmenopausal women. The ef-
fect of obesity on osteoporosis, as reflected by the relationship
between obesity and BMD, was also analyzed.
Methods
Study subjects In this cross-sectional study, the subjects com-
prised of 382 postmenopausal women (ages ≥45 years) were
recruited from various clinics and community centers from the
central part of the West Bank region of Palestine. All recruited
subjects were not previously diagnosed with bone problems or
suffer from bone-related health conditions and had no previous
BMD assessment. In addition, none of the subjects suffered
from any medical complication that affected bone health status
and were not using any prescription drugs or food supplements
(including vitamin D and calcium) that affected their general
bone status. All subjects were referred to a special clinic and
were medically checked for their vital signs, their height and
weight were recorded, and BMI was calculated. All subjects
were interviewed by the medical staff of the clinic to fill a
special questionnaire concerning their life style and general
health information that was designed, tested, and used previ-
ously by our group [34]. Blood samples were collected from all
subjects; serum was immediately separated and stored frozen
until the level of specific serum bone-related markers was mea-
sured. All study subjects were required to sign a consent form
declaring their agreement to participate in the study. Ethical
approval for the study protocol was obtained from the
Research Ethics Committee of Al-Quds University in Palestine.
Bonemineral density and serum bonemarkers assessment
BMD was assessed using dual energy x-ray absorptiometry
DXA (Lunar Prodigy GE) at the total hip, femoral neck, and
lumbar (L1–L4) spine. Measurements of BMDwere very pre-
cise (coefficient of variation (CV) = 0.28%). Serum 25(OH)D
(CV = 2.33% and 6.45% for intra- and inter-assay, respective-
ly) and PTH (CV = 2.08% and 1.75 for intra- and inter-assay,
respectively) were measured by chemiluminescence using
Architect 1000 (Abott, USA). Serum calcium was measured
by a calorimetric end point method. CTX and PINP
(CV < 10%) were measured by ELISA. Osteoporosis is de-
fined as having a T score ≤ −2.5 at any of the three tested sites.
Statistical analysis SPSS program was utilized for all data
entry and related analysis that included frequencies, descrip-
tive statistics, and bivariate correlations (Pearson’s). Simple
linear, multiple, and logistic regression analyses were also
performed on the data to assess the correlation between
BMD and the various indicated variables. Chi-square test
(two-sided) was performed in order to identify differences in
categorical variables between subgroups and independent t
test for continued variable. One-way analysis of variance
(ANOVA) was undertaken to assess differences in means of
calcium and PTH by vitamin D groups. Significance levels of
less than 5% were considered significant.
Results
Table 1 of univariate analysis showed that mean values of
weight, height, and BMI were significantly lower
(p < 0.0001) in women with osteoporosis, while their mean
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age was significantly higher compared to normal control sub-
jects (68.2 vs. 61.3 years, respectively, p < 0.0001). The mean
values of BMI for both groups were above 30 kg/m2, which
indicated that osteoporosis and control subjects were obese.
No significant differences were detected between mean values
of calcium, 25(OH)D, PTH, and bone turnover markers
(CTX1 and PINP) in women with osteoporosis compared to
controls. Due to the fact that there was a significant difference
in the mean age between control and osteoporosis groups, the
differences between the indicated markers (vitamin D, Ca,
PTH, CTX1, and PINP) were reevaluated after taking a subset
of the control group with a mean age that matches the mean
age of the osteoporosis group. Similar results were obtained
that ruled out the differences between the indicated markers
being due to age (data not shown).
Table 2 showed that 14.1% of the study subjects had severe
vitamin D deficiency (< 10 ng/ml 25(OH)D with mean ± SD
8.51 ± 1.28 ng/ml), whereas 71.8% had vitamin D insufficiency
or borderline [25(OH)D 10 to < 20 ng/ml with mean ± SD
13.26 ± 2.20 ng/ml]. Subjects with normal (vitamin D suffi-
cient) represented 14.1% [25(OH)D ≥ 20 ng/ml with
mean ± SD 24.55 ± 3.60 ng/ml] [7, 39]. Chi-square analysis
showed no statistically significant difference in the prevalence
of vitamin D groups between osteoporosis and control subjects.
Table 2 also showed the levels of calcium and PTH in subjects
in the three vitamin D groups. ANOVA showed that mean
serum calcium levels were significantly higher in subjects with
vitamin D sufficiency compared to serum calcium levels in
subjects with severe vitamin D deficiency or vitamin D insuf-
ficiency (p = 0.022). However, it should be indicated that serum
calcium levels in the three groups were within the normal range.
When PTH levels were compared in the three groups, ANOVA
showed that mean values of PTH levels were significantly low-
er in subjects with vitaminD sufficiency (p < 0.0001) compared
to vitamin D insufficiency or severe vitamin D deficiency
subjects. The mean values of PTH were not statistically
different between severe vitamin D deficiency and vitamin D
insufficiency subjects. Approximately, 27% of recruited subject
had previous accident that caused broken bones with no
difference between osteoporotic and control subjects.
A scatter plot showing the relationship between vitamin D
and PTH is depicted in Fig. 1. Vitamin D was negatively
correlated with PTH in all subjects (r = −0.295, p < 0.01) as
well as in osteoporosis subjects (r = −0.30, p < 0.01).
Table 3 showed the Pearson correlation coefficients of the
parameters measured in the tested subjects. Serum 25(OH)D
was significantly negatively correlated with PTH, weight,
and BMI and positively correlated with calcium. No statis-
tically significant correlations were detected between vita-
min D and BMD at the three indicated sites (total hip, fem-
oral neck, and lumbar L1–L4 spine), as well as with age,
height, bone resorption (CTX1), and bone formation (PINP)
markers. Age was negatively correlated with BMD (total
hip, femoral neck, and lumbar L1–L4 spine), height, weight,
and BMI. Pearson correlation showed the markers for bone
resorption (CTX1) and bone formation (PINP) were
Table 1 Mean values related to osteoporosis in normal and osteoporosis women
Parameter Control Osteoporosis p value
Mean ± STD (N) Mean ± STD (N)
Age 61.3 ± 7.98 (251) 68.2 ± 8.55 (131) <0.0001
Weight Kg 82.2 ± 13.39 (251) 71.4 ± 11.82 (131) <0.0001
Height cm 157.2 ± 7.28 (251) 153.6 ± 7.51 (131) <0.0001
BMI 33.1 ± 5.28 (247) 30.4 ± 5.29 (131) <0.0001
CTX1 pg/ml 6526 ± 4323 (151) 6857 ± 4313 (121) 0.531
PINP μg/l 549 ± 330 (150) 567 ± 342 (120) 0.654
Ca mg/dl 9.38 ± .50 (157) 9.28 ± 0.56 (122) 0.121
Vitamin D ng/ml 14.1 ± 4.85 (154) 13.6 ± 4.82 (123) 0.396
PTH pg/ml 70.7 ± 32.3 (155) 75.2 ± 33.3 (121) 0.253
Total hip BMD gm/cm2 0.979 ± 0.131 (242) 0.780 ± 0.114 (128) <0.0001
Femoral neck BMD gm/cm2 0.888 ± 0.125 (248) 0.695 ± 0.091 (130) <0.0001
Lumbar spine BMD gm/cm2 1.100 ± .154 (248) 0.858 ± 0.139 (130) <0.0001
Total hip T score −0.220 ± 1.030 (242) −1.817 ± 0.911 (128) <0.0001
Femoral neck T score −1.122 ± 0.829 (244) −2.466 ± 0.648 (130) <0.0001
Lumbar spine T score 0.683 ± 1.262 (247) −2.708 ± 1.179 (130) <0.0001
p values are independent t test
STD standard deviation,N number of subjects, BMI bodymass index,PINP procollagen type I N propeptide,CTX1 serumC-terminal telopeptide of type
I collagen, PTH parathyroid hormone, BMD bone mineral density
Arch Osteoporos  (2017) 12:13 Page 3 of 8  13 
positively correlated (r = 0.529, p < 0.01). This correlation
between bone-remodeling markers was very strong in sub-
jects with osteoporosis (r = 0.887, p < 0.000) whereas no
correlation was seen in normal control subjects (r = 0.03,
p = 0.74). Among control subjects, PINP was negatively
correlated with femoral neck BMD (r = −0.199,
p = 0.015) and height (r = −0.173, p = 0.034) and positively
correlated with BMI (r = 0.190, p = 0.021). Calcium levels
were positively correlated with vitamin D levels and BMD
of total hip, whereas calcium was negatively correlated with
PTH. These correlations, despite being significant, were not
strong. Body mass index was positively correlated with
BMD (in total hip, femoral neck, and lumbar L1–L4 spine)
and PTH and negatively correlated with vitamin D.
Correlations within the osteoporosis group were also
investigated. No significant correlations were seen be-
tween calcium and vitamin D, calcium and PTH, BMI
and vitamin D, BMI and PTH, BMI and femoral neck
BMD, BMI and age, and height and BMD at the three
sites. Lumbar spine BMD was positively correlated with
vitamin D (r = 0.193, p = 0.033), negatively correlated
with PTH (r = −0.198, p = 0.030), and not correlated with
height and age.
To determine which variables could predict the BMD level
when controlling for the effect of others at each of the tested
locations, multiple regression was performed on all variables
(Table 4). The results showed that irrespective of the location,
both age and weight of the participants appeared to be signif-
icant determinants of BMD. Weight appeared to have a posi-
tive medium effect on BMD at all locations, whereas age was
a negative predictor that lost some of its correlation strength
with BMD in the lumbar spine. All other variables did not
show any association with BMD at any tested location, except
for vitamin D, which appeared to have an effect on the lumbar
spine. The models in Table 4 suggested that the variables
entered in the analysis had the strongest predictive effect on
Fig. 1 Scatter plot of parathyroid
hormone against vitamin D
Table 2 Frequency of subjects and serum calcium and parathyroid hormone levels in different vitamin D groups
Parameter 25(OH)D3 p value
≥20 ng/ml 10 to <20 ng/ml <10 ng/ml
Normal (sufficiency) Insufficiency (borderline) Severe deficiency
Osteoporosis N (%) 15 (12%) 94 (75%) 16 (13%) 0.52
Control N (%) 25 (16%) 110 (69%) 24 (15%)
Total N (%) 40 (14.1%) 204 (71.8%) 40 (14.1%)
Ca mg/dl 9.55 ± 0.52 (39) 9.30 ± 0.51 (202) 9.21 ± 0.59 (38) 0.022
PTH pg/ml 49.3 ± 19.8 (39) 75.2 ± 31.8 (198) 83.3 ± 37.6 (39) <0.0001
PTH and Ca values are mean ± STD (N)
N number of subjects, PTH parathyroid hormone, Ca calcium
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total hip BMD (R2 = 0.34) but less predictive effect on BMD
of femoral neck (R2 = 0.29) or lumbar spine (R2 = 0.225).
To test which variable has a significant effect that could be
a determinant on the probability that the tested subject would
become osteoporotic, binary logistic regression was carried
out (Table 5). The results showed that age and obesity status
of the subject could be important determinants of osteoporo-
sis. Age progression appeared as a risk factor with odds ratio
(OR) = 1.1 (1.05–1.15). Obesity status was protective against
osteoporosis development with a borderline effect for being
overweight (OR = 0.11, p = 0.053) and a very clear effect for
being obese (OR = 0.05, p = 0.007). The protective effect of
obesity on the development of osteoporosis was only seen in
the total hip of obese subjects (OR = 0.195, p = 0.04) but not
in overweight subjects. Among all models tested, the overall
osteoporotic status model was the strongest in terms of its
predictive power and joint effect of the significant variables
on the change in the status compared to individual sites. Age
was the only significant predictor at all sights and the only
significant predictor for osteoporotic development in the fem-
oral neck and lumbar spine.
Discussion
The present data showed vitamin D deficiency to be common
among Palestinian postmenopausal women which is consis-
tent with the widespread vitamin D deficiency in Palestine
[39] andMiddle Eastern Arab countries [15, 27, 40]. The level
of vitamin D depends on several factors including diet, expo-
sure to sun, age, feeding habits, life style, metabolic, genetic,
and other environmental factors [7, 41]. In Palestine, like the
rest of Middle Eastern countries, adequate sunshine is avail-
able throughout the whole year; however, exposure of women
Table 3 Pearson correlation between different bone-remodeling parameters related to osteoporosis
Parameter Age
years
Weight
Kg
Height
cm
BMI
Kg/m2
PINP
μg/l
CTX1
pg/ml
Ca
mg/dl
Vit. D
ng/ml
PTH
pg/ml
BMD
hip
BMD
neck
BMD
L1–L4
Age years 1
Weight Kg −0.263** 1
Height cm −0.219** 0.223** 1
BMI Kg/m2 −0.134** 0.841** −0.305** 1
PINP μg/l 0.066 −0.005 −0.076 0.056 1
CTX1 pg/ml 0.038 −0.007 −0.048 −0.024 0.529** 1
Ca mg/dl −0.083 0.008 0.028 0.007 −0.014 −0.106 1
Vit. D ng/ml −0.039 −0.148* 0.035 −0.148* 0.071 0.008 0.169** 1
PTH pg/ml −0.014 0.104 −0.109 0.129* 0.078 0.112 −0.132* −0.295** 1
BMD hip gm/cm2 −0.431** 0.444** 0.192** 0.321** −0.059 −0.059 0.122* 0.001 −0.024 1
BMD neck gm/cm2 −0.459** 0.394** 0.233** 0.255** −0.096 −0.004 0.072 0.014 −0.011 0.866** 1
BMD L1–L4 gm/cm2 −0.276** 0.425** 0.230** 0.279** −0.073 −0.102 0.111 0.078 −0.045 0.649** 0.625** 1
*Correlation is significant at the 0.05 level (two-tailed)
**Correlation is significant at the 0.01 level (two-tailed)
BMD hip total hip BMD, BMD neck femoral neck BMD, BMD L1–L4 lumbar (L1–L4) spine BMD, BMD bone mineral density, BMI body mass index,
PINP procollagen type I N propeptide, CTX1 serum C-terminal telopeptide of type I collagen, PTH parathyroid hormone
Table 4 Association of bone marker variables with BMD by location using multiple regression analysis
BMD gm/cm2 Model R2 CTX1
pg/ml
PINP
μg/l
Ca
mg/dl
Vit. D
ng/ml
PTH
pg/ml
Age
years
Weight
Kg
Height
cm
Total hip 0.340 p value 0.85 0.510 0.969 0.946 0.124 <0.0001 <0.0001 0.505
Adjusted R −0.013 0.048 0.003 −0.005 −0.112 −0.34 0.425 −0.049
Femoral neck 0.295 p value 0.096 0.306 0.508 0.348 0.690 <0.0001 <0.0001 0.711
Adjusted R 0.119 −0.073 −0.047 0.067 −0.029 −0.364 0.346 0.027
Lumbar spine 0.225 p value 0.136 0.778 0.808 0.038 0.217 0.021 <0.0001 0.491
Adjusted R −0.107 0.02 0.018 0.149 −0.089 −0.166 0.335 0.05
BMD bonemineral density, PINP procollagen type I N propeptide,CTX1 serumC-terminal telopeptide of type I collagen,PTH parathyroid hormone,Ca
calcium, Vit. D 25(OH)D3
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to sunlight is limited due to cultural and social factors. In
addition, poor awareness of the disease, absence of screening
programs, and poor advice on the need for regular consump-
tion of dairy products and vitamin D-rich food largely contrib-
ute to the observed high vitamin D deficiency among post-
menopausal women. Moreover, poor socioeconomic condi-
tions including limited income and large family size add ad-
ditional complications to the problem [34]. In addition, iron
deficiency is common among the Palestinian population [39]
and intestinal absorption of vitamin D is influenced by iron
metabolism which provides an additional factor in determin-
ing serum vitamin D levels [42].
Clearly, the inverse correlation between vitamin D level
and PTH was evident. Our results showed no correlation be-
tween vitamin D and BMD levels and mean vitamin D levels
were not significantly different between osteoporotic and con-
trol groups. However, a positive correlation between vitamin
D and lumbar spine BMD in Pearson correlation of osteopo-
rosis postmenopausal women subgroup and in multiple re-
gression analysis was seen and indicated differential effect
of vitamin D on BMD at this site. Even though multiple re-
gression analysis showed significant effect on BMD of lumbar
spine, logistic regression analysis showed this effect was not
enough to affect the status of osteoporosis among tested sub-
jects. This is in agreement with previous studies in Lebanon,
Saudi Arabia, United Arab Emirates, and Iranian postmeno-
pausal women that found no correlation between
25(OH)vitamin D and BMD [10, 40, 43–45] and in other
counties [12, 46–48]. The lack of correlation between BMD
and serum 25(OH)vitamin D does not exclude a correlation of
BMD with intracellular active 1,25(OH)2 D3 produced in all
tissues including bone cells that exerts its function through an
autocrine effect [49, 50].
The cutoff value for vitamin D using PTH levels as refer-
ence was 14.3 ng/ml which represents the optimum vitamin D
levels that prevents secondary hyperparathyroidism among
the tested subjects. This value is comparable to the vitamin
D cutoff value (15.4 ng/ml) determined by similar analysis in
a study of hypovitaminosis among college students in a coun-
try in the same region [51] and in contrast to 30 ng/ml in the
Spanish community [52]. These reflection points are not reli-
able and are not used to derive desirable vitamin D levels. The
increase in PTH due to a decrease in vitamin D that was not
reflected dramatically on calcium levels that remained within
the normal range is probably due to the effect PTH on bone
and kidney and the effect of vitamin D on calcium absorption.
As expected, the observed effect of vitamin D on PTH in this
study is mediated through calcium since calcium levels are
significantly lower in subjects with severe vitamin D deficien-
cy leading to increased PTH levels.
The negative correlation of age with BMD was obvious at
the three bone sites (total hip, femoral neck, and lumbar L1–
L4 spine). This is consistent with the fact that during the pro-
cess of bone remodeling, bone formation takes less time than
resorption [2, 53, 54]. Similar to the effect of vitamin D, no
correlation was evident between BMD and serum calcium,
PTH, PINP (bone formation marker), and CTX1 (bone resorp-
tion marker). However, a significantly higher level of bone
remodeling was evident in the osteoporosis group as reflected
by the high correlation between PINP and CTX1 in these
subjects compared to the absence of correlation in the control
group between the indicated markers. These results are con-
sistent with the understanding that BMD is determined by
complex interactions between genetic and non-genetic factors
that play a role in determining the final bone health status [2].
Eventually, higher rate of bone remodeling in osteoporosis
Table 5 Logistic regression analysis for predictors of osteoporosis occurrence by location
Osteoporosis occurrence at any location Total hip Femoral neck Lumbar spine
R2 of the model 0.287 0.162 0.236 0.25
p value OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value OR (95% CI)
CTX1 pg/ml 0.280 1.00 0.52 1.00 0.41 1.00 0.07 1.00
PINP ug/L 0.437 1.00 0.23 1.00 0.29 1.00 0.48 1.00
Ca mg/dl 0.878 0.94 (0.46–1.91) 0.54 0.811 (0.41–1.60) 0.25 1.66 (0.69–3.98) 0.88 0.943 (0.41–2.14)
PTH pg/ml 0.078 1.00 0.26 1.00 0.26 1.00 0.99 1.00
Age 0.001 1.10 (1.05–1.15) 0.005 1.058 (1.01–1.10) 0.002 1.09 (1.03–1.15) 0.001 1.10 (1.05–1.16)
Vit. D status (trend) (0.307) (0.46) (0.60) (0.20)
Insufficient 0.370 1.58 (0.57–4.36) 0.80 1.131 (0.43–2.95) 0.32 0.48 (0.11–2.02) 0.07 2.62 (0.90–7.61)
Deficient 0.835 0.87 (0.25–3.04) 0.51 0.672 (0.20–2.20) 0.48 0.54 (0.09–2.99) 0.19 2.43 (0.63–9.37)
Obesity status (trend) (0.004) (0.01) (0.006) (0.41)
Overweight 0.053 0.11 (0.01–1.03) 0.34 0.452 (0.08–2.33) 0.95 1.07 (0.10–11.39) 0.99 1.00
Obese 0.007 0.05 (0.006–0.45) 0.04 0.195 (0.04–0.95) 0.14 0.20 (0.02–1.74) 0.99 1.00
PINP procollagen type I N propeptide,CTX1 serumC-terminal telopeptide of type I collagen, PTH parathyroid hormone,Ca calcium, Vit. D 25(OH)D3,
OR odds ratio
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may lead to reduced stability in bone strength and could pro-
vide an explanation for the higher fracture risk in osteoporotic
compared to non-osteoporotic individuals [13].
An additional complication in our understanding of osteo-
porosis was the effect of obesity on bone health. Our data
showed that obesity had a positive correlation with BMD in
the spine, total hip, and femoral neck and was protective
against osteoporosis which is consistent with several previous
reports [34, 55–60]. On the other hand, our data also showed
that obesity had a negative correlation with vitamin D and a
positive correlation with PTHwhich may indicate that obesity
is a risk factor for osteoporosis which has been also shown by
other investigators [61–65]. The overall effect of obesity
seems to be protective since the number of osteoporotic sub-
jects among obese postmenopausal women was significantly
lower than that in overweight and normal weight subjects and
the odds ratio of being osteoporotic is lower in obese com-
pared to overweight and normal weight. Other investigators
found that obesity was correlated with increased selective
bone fracture risk independent of the positive effect on
BMD levels which indicate that bone health and osteoporosis
development result from a complicated multifactorial process
[63, 66–68]. Furthermore, since obesity constitutes a strong
risk factor for diabetes, the associated low vitamin D levels,
decreased insulin secretion, and or decreased insulin sensitiv-
ity contribute to the complexity of the effect of obesity on
bone health [63].
In conclusion, the present study showed no direct correla-
tion between BMD and vitamin D (except at lumbar spine),
bone formation (PINP) and resorption (CTX1) markers, and
PTH and calcium (except at hip). There were also no differ-
ences in mean values of vitamin D between control and oste-
oporosis postmenopausal women. The apparent protective ef-
fect of obesity on osteoporosis based on the effect of obesity
on BMD masks the effect of obesity on vitamin D, PTH, and
obesity-induced insulin resistance. Some of the limitations of
this study were the absence of external quality control for
vitamin D, PTH, and bone turnover markers and the absence
of local data base to be used for identifying subjects with
osteoporosis. Also, fracture data was obtained from recruited
subjects not because of the absence of medical records. More
focused studies are needed to understand the interaction be-
tween these factors and other signaling and genetic factors on
osteoporosis.
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